Atlas Venture

Quartet Medicine, Merck partner

Thursday, January 7, 2016

Quartet Medicine, a biotechnology company focused on the development of novel treatments for chronic pain and inflammation, has entered into a strategic agreement with Merck, known as MSD outside the U.S. and Canada, in connection with Quartet’s pipeline of novel small molecule drugs modulating the tetrahydrobiopterin (BH4) pathway.

[Read More]

Intellia Therapeutics, Novartis partner

Wednesday, January 7, 2015

Intellia Therapeutics, a Cambridge, Mass.-based developer of therapeutic products using CRISPR/Cas9 technology for gene editing and repair, has announced a five-year R&D collaboration with Novartis to accelerate the ex vivo development of new CRISPR/Cas9-based therapies using chimeric antigen receptor T cells (CARTs) and hematopoetic stem cells (HSCs).

[Read More]

Amgen, Novartis partner with Atlas Venture

Wednesday, November 19, 2014

Atlas Venture, based in Cambridge, Mass., has entered into corporate strategic partnership (CSP) agreements with both Amgen, through its venture capital fund, Amgen Ventures, and Novartis. Atlas IX is expected to create and/or fund more than 15 new biotech companies and anticipates these new CSP relationships will be integral parts of facilitating their launch and progression.    

[Read More]

Fidelity Biosciences and Atlas Venture launch Unum Therapeutics

Wednesday, October 22, 2014

Fidelity Biosciences and Atlas Venture, with participation from SanofiGenzyme BioVentures, have launched Unum Therapeutics, a company developing cellular immunotherapy to treat cancer. Fidelity Biosciences invests venture capital in biopharmaceutical, medical technology, healthcare information technology and healthcare service companies, while Atlas Venture is an early-stage investor. All three are based in Cambridge, Mass.

[Read More]